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Abstract
Background:  Complementary and alternative medicines are used by many consumers, and
increasingly are being incorporated into the general practitioner's armamentarium. Despite
widespread usage, the evidence base for most complementary therapies is weak or non-existent.
Post-antibiotic vulvovaginitis is a common problem in general practice, for which complementary
therapies are often used. A recent study in Melbourne, Australia, found that 40% of women with a
past history of vulvovaginitis had used probiotic Lactobacillus species to prevent or treat post-
antibiotic vulvovaginitis. There is no evidence that this therapy is effective. This study aims to test
whether oral or vaginal lactobacillus is effective in the prevention of post-antibiotic vulvovaginitis.
Methods/design: A randomised placebo-controlled blinded 2 × 2 factorial design is being used.
General practitioners or pharmacists approach non-pregnant women, aged 18–50 years, who
present with a non-genital infection requiring a short course of oral antibiotics, to participate in the
study. Participants are randomised in a four group factorial design either to oral lactobacillus
powder or placebo and either vaginal lactobacillus pessaries or placebo. These interventions are
taken while on antibiotics and for four days afterwards or until symptoms of vaginitis develop.
Women self collect a vaginal swab for culture of Candida species and complete a survey at baseline
and again four days after completing their study medications. The sample size (a total of 496 – 124
in each factorial group) is calculated to identify a reduction of half in post-antibiotic vulvovaginitis
from 23%, while allowing for a 25% drop-out. An independent Data Monitoring Committee is
supervising the trial. Analysis will be intention-to-treat, with two pre-specified main comparisons:
(i) oral lactobacillus versus placebo and (ii) vaginal lactobacillus versus placebo.
Background
Use of complementary and alternative medicines (CAM)
by the lay public and doctors remains a topic of contro-
versy. In Australia and the United States, the estimated
annual expenditure associated with CAM usage is
$AUD2.3 billion and $US27.1 billion respectively, which
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is more than that spent on prescription medicines [1,2].
There is a relative lack of an evidence-base for CAM [3,4],
which was emphasised by recent calls from a Health Min-
ister for an investigation into whether health insurance
funds should reimburse for use of unproven CAM thera-
pies [5]. However, scant resources are available for CAM
research [6,7] and the accepted method of assessing med-
ical therapies, randomised controlled trials, can be chal-
lenging to apply to CAM [7,8].
A common condition of concern to women, the largest
consumers of CAM [1,9], is post-antibiotic vulvovaginitis
(PAV) [10], usually caused by Candida albicans [11]. In our
recent survey of Australian women, 40% of a sample of
751 with a past history of vulvovaginitis had used yoghurt
or lactobacillus orally and/or vaginally to prevent PAV
[10]. Other countries have found similar high rates of use
for vaginal symptoms of lactobacillus products [12,13],
which are also recommended by natural medicine practi-
tioners for vulvovaginitis [14].
Although lactobacillus is commonly recommended and
used for PAV, a thorough literature search using the terms
lactobacillus, vagina, Candida and Cochrane Collabora-
tion search strategies for randomised controlled trials,
revealed no trials which had tested whether lactobacillus
is effective in the prevention of PAV, although several tri-
als have examined lactobacillus in recurrent vulvovagin-
itis. Most of these trials were methodologically poor
(inadequate allocation concealment, not randomised, no
controls and/or not intention-to-treat analysis) [15-18];
in the most recent trial in women with HIV, the lactoba-
cillus arm failed to reach statistical significance in the pre-
vention of vulvovaginal candidiasis [19].
This study aims to test in a randomised controlled trial
whether oral and/or vaginal lactobacillus preparations
can prevent post-antibiotic vulvovaginitis.
Methods/design
Study design
The PAV study uses a randomised controlled blinded 2 ×
2 factorial design, with four intervention groups (see fig-
ure 1). The factors are oral lactobacillus, oral placebo, vag-
inal lactobacillus and vaginal placebo. The design and
analysis assumes that there will be no interaction between
the oral and vaginal interventions. There are two pre-spec-
ified main comparisons: (i) oral lactobacillus versus pla-
cebo and (ii) vaginal lactobacillus versus placebo.
Study population
Inclusion criteria
The inclusion criteria are: women aged between 18 and 50
years of age [20,21]; who are experiencing a non-genital
infection; requiring a short-course of oral antibiotics or
have commenced this within the 48 hours preceding
enrolment; and English-speaking – able to speak, read
and write in English sufficiently to provide informed con-
sent and complete surveys.
Exclusion criteria
Exclusion criteria are: pregnancy; experiencing any vaginal
symptoms at recruitment; unwilling or unable to provide
two self-collected low vaginal swabs (at recruitment and
on completion of trial); using or have used vaginal anti-
fungal treatments in the past two weeks [21]; have taken
antibiotics in the past month [22]; unwilling to stop tak-
ing other lactobacillus products during the trial; or immu-
nocompromised, as there are rare reports in the literature
of lactobacilli causing endocarditis and bacteraemia [23].
Sample size
The sample size calculation is based on a local incidence
rate of PAV of 23% [10] with a power of 80% and signifi-
cance level of 5% for a 2-sided test. To detect a clinically
meaningful 50% reduction in the incidence of PAV, a total
of 93 women are required in each arm of the study. Allow-
ing for a 25% drop out rate, 124 women are required in
each of the four arms, which equates to a planned total of
496 women.
Randomisation
Sequence
Block randomisation in batches of eight using computer-
generated random numbers is being used to assign
women to one of the four combinations of trial interven-
tion. Block randomisation was chosen to ensure that the
experimental groups would not become unbalanced if the
rate of recruitment at sites differed greatly. A total of eight
in each batch is used as most general practice clinics have
limited space in their vaccination refrigerators and eight
intervention pairs is considered the most that could be
reasonably accommodated at one time.
Allocation concealment
A research fellow with no other role in the project is over-
seeing the labelling and packing of all the trial medica-
tions and holding the randomisation schedule until the
code is broken.
Implementation
Batches of eight intervention pairs, numbered sequen-
tially, are provided to community-based recruiters or kept
centrally in a dedicated refrigerator at the Department of
General Practice for use by the mobile recruitment team.
Recruiters are instructed to use the lowest numbered inter-
vention first and then continue consecutively.BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/5
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Trial design Figure 1
Trial design
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Blinding
Participants, recruiters and microbiology staff responsible
for processing the participants' specimens are blinded to
group allocation. The success of masking of participants is
checked with a question in the final survey. Community
recruiters do not have access to microbiology results and
microbiologists do not know the symptom status or iden-
tity of participants.
Interventions
Many women report using yoghurt to prevent or treat
post-antibiotic vulvovaginitis. However, this was not seri-
ously considered as an option for this study, due to its
instability [24], relatively short shelf life, lower standard
of quality control (manufacture is regulated by food
rather than pharmaceutical standards [16]); presumed
lack of acceptability to some women for vaginal use; and
difficulty of standardising a per vaginum dose.
The interventions being tested in the 2 × 2 factorial design
are:
(i) oral powder: either Lactobac – containing Lactobacillus
rhamnosus and Bifidobacterium longum or placebo – malto-
dextrin powder; and
(ii) vaginal pessaries: either Femilac – L. rhamnosus, L. del-
brueckii, L. acidophilus and  Streptococcus thermophilus or
placebo – malto-dextrin pessaries.
The oral dose chosen is half a teaspoon of powder twice
daily 20 minutes before meals; the per vaginum regimen
is one pessary to be inserted high into the vagina with a
supplied applicator at bedtime for ten days, whilst taking,
and continued for four days after completion of, the anti-
biotic course. Ten days is felt to be a reasonable balance
between a minimum to be effective and a maximum, to
which women would adhere for prevention of a possible
side-effect.
Women enrolled in the trial sometimes require additional
days of antibiotics for various clinical reasons. When this
occurs, the courses of oral and vaginal interventions are
extended to last until four days after the antibiotics cease,
if the participant agrees. To deal with this circumstance,
the research fellow responsible for maintaining allocation
concealment directs which intervention code numbers to
use to provide the woman with additional trial medica-
tion, which preserves the same study group to which the
woman was originally allocated.
Recruitment
Recruitment network
Recruitment for the trial is through a network of commu-
nity-based general practice clinics and pharmacies. Gen-
eral practitioners (GPs) have been trained to identify
potential participants and to introduce the trial to them. If
women are eligible and consent to participating, then the
GP could either recruit themselves, or refer to a mobile
recruitment team, consisting of MP, POM and KN. Some
community-based pharmacists are also trained to inform
women about the trial, when dispensing antibiotics.
Enrolment of participants
Recruiting GPs identify eligible women in their clinical
practice and invite them to consider participation in the
trial, after provision of sufficient information to make an
informed decision (see appendix 1 (Additional file 1) for
the plain language statement). Women who meet the eli-
gibility criteria and agree to participate are required to give
written informed consent (see appendix 2 (Additional file
2) for the consent form). All women eligible to partici-
pate, including women who decline to participate, are
asked for permission for the GP to complete the PAV
Recruitment sheet, that is a log of all potential participants
to check whether the study population is representative of
the entire eligible population in key criteria related to the
outcomes of interest. Recruiting GPs also obtain demo-
graphic and relevant past and current medical data, partic-
ularly data relevant to risk factors for developing
vulvovaginal candidiasis (see appendix 3 (Additional file
3) Recruiter Survey).
To refer the woman to the mobile recruitment team, the
GP or pharmacist can provide women with a 'spotter flyer'
(see appendix 4 (Additional file 4) spotter flyer) with
information about the trial and contact details. The GP,
pharmacist or woman herself can call the mobile recruit-
ment team on a mobile telephone dedicated to the trial.
The team member will talk to the woman, establish her
eligibility, explain the trial and then arrange a mutually
agreeable time to recruit at the woman's home or work-
place on that day, in a similar manner to that described for
general practitioners. The mobile recruitment team is
available seven days a week, as it is essential to commence
the interventions as soon as possible after the course of
antibiotics has commenced.
Data collection
At enrolment, participants complete a baseline survey (see
appendix 5 (Additional file 5) survey 1) and, after appro-
priate written instruction (see appendix 6 (Additional file
6)'Instructions for taking your vaginal swab'), provide
their own vaginal swab ("swab A"). A second swab ("swab
B") and survey (see appendix 7 (Additional file 7) survey
2) are required four days after completing the interven-
tion, generally 14 days after recruitment or at the time of
developing symptoms of vaginitis.BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/5
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After randomisation into a study group, women are sup-
plied with a unique PAV identity number, a PAV Take
Home Kit and their intervention powder and pessaries.
The PAV Take Home Kits, all their contents and the inter-
vention medications each have the same PAV identity
number. The kits contain surveys 1 and 2 with reply paid
envelopes, swabs A and B with labelled microbiology
request forms and specimen bags, the laboratory's address
and courier instructions printed on courier envelopes, a
prepaid courier voucher, a Frequently Asked Questions
brochure (see appendix 8 (Additional file 8) FAQs), a PAV
logo sticker with the date when swab B is due written by
the recruiter and two PAV logo refrigerator magnets with
PAV team contact details.
The baseline survey requests basic demographic informa-
tion such as age, country of birth, level of education and
postcode; self-assessment of likelihood of PAV; type of
antibiotic prescribed and infection; other risk factors for
developing vulvovaginal candidiasis; weight and height to
calculate body mass index (BMI); whether sexually active
and any other medical conditions. Survey 2 requests infor-
mation about participants' adherence to the antibiotic,
oral and vaginal intervention regimes; any symptoms of
PAV or side-effects of the intervention; whether partici-
pants think they were allocated real or placebo interven-
tions and how effective the interventions were.
The microbiology specimens are collected and trans-
ported within 24 hours to the Royal Children's Hospital
laboratory, Women's and Children's Health, Melbourne,
Australia. Swabs at recruitment are either transported by
the mobile team or by local pathology companies. A cou-
rier company collects swab Bs from a location convenient
to the participants.
Self-collected vaginal swabs are initially rolled on to a
glass slide for Gram stain examination microscopically.
The swabs are then rolled on to a half CHROMagar
medium (CHROMagar, Paris) [25] and incubated at
35°C. for two days. Candida albicans, C. glabrata, and C.
krusei  are identified by specific colour of colonies on
CHROMagar; other candida species are identified by
ID32C kit (BioMérieux, France) [26].
Follow-up of participants
There are several phases of follow-up once women enter
the trial.
• Women recruited by GPs are telephoned the day after
recruitment to check that they are clear about their com-
mitment, still consent to participate and to answer any
queries.
• A letter is mailed to all women approximately one week
after recruitment, to welcome them to the study and
reconfirm the due date for swab B.
• Participants who do not return survey 2 or swab B are
followed-up within one week with telephone calls, and if
necessary letters, to obtain information about any symp-
toms of PAV.
• All women who report no symptoms of PAV at day 14,
but whose swab B culture Candida species, are contacted
at least one week after trial completion to ascertain
whether symptoms of PAV developed.
Women who develop symptoms of PAV during the trial
Women have printed instructions in their PAV Kit about
how to respond if symptoms of vaginitis develop during
the trial. The main message is to obtain swab B prior to
any treatment for symptoms. Women may contact a
member of the research team on the mobile PAV tele-
phone number, who will be available daily until 10 pm
and can arrange for either a courier or herself to collect the
swab that day for delivery to the laboratory. Once the
swab is taken, even prior to discussing the situation with
the PAV team, women are encouraged to treat themselves
in their usual manner. Women may elect to attend their
GP to have swab B taken.
Quality control
Run-in phase
The initial 25 participants and their recruiting general
practitioners have been interviewed by telephone by MP
to seek ways to improve the study method.
Intervention
Adequate storage of the trial medications requires refriger-
ation between 2 and 8 degrees Celsius. Recruiting clinics
are required to ensure adequate storage of their eight pairs
of PAV medication in the clinic vaccine refrigerator, which
have continual temperature recordings to comply with
practice accreditation standards.
Prior to study commencement of the trial, once during
recruitment and again at the end of the trial, randomly
chosen intervention medications are subjected to inde-
pendent microbiological examination (Royal Children's
Hospital, Melbourne, microbiology laboratory), to con-
firm that the lactobacillus species are viable and that the
labelling of active and placebo medication is correct.
Microbiology
All microbiological specimens are being processed in the
one laboratory (Department of Microbiology and Infec-
tious Diseases, Royal Children's Hospital, Women's and
Children's Health, Melbourne, Australia) to ensure con-BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/5
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sistency of processing and reporting. Even if women
develop PAV symptoms and opt to attend their GP for
management, the GPs are requested to forward the speci-
mens to the preferred trial laboratory.
Data entry
The trial databases are constructed with stringent checking
criteria to prevent mistakes in data entry. Research assist-
ants receive adequate training and support to ensure thor-
ough understanding of the process for data entry. Ten
percent of surveys are audited to ensure high standards of
accuracy and reliability of interpretation prior to any data
processing. Data cleaning and checking is undertaken
using several strategies, commencing with the construc-
tion of the database in Microsoft Access and also using
Stata [27].
Women's participation
Several questions in survey 2 check the process of
women's participation in the trial. These questions regard
compliance with and side-effects of both antibiotics and
study medications; the experience of providing a vaginal
swab; willingness to pay for the study medications if they
are effective; and participants' opinions as to whether they
are allocated to lactobacillus or placebo medications and
whether the medications were effective.
Data monitoring committee
An independent Data Monitoring Committee oversees the
conduct of the trial. The committee comprises of Professor
Judith Lumley (chair – Director of the Centre for Study of
Mothers' and Children's Health, La Trobe University and
professor of perinatal epidemiology), Dr Susan Hurley
(pharmacologist and epidemiologist), Dr Sonia Grover
(gynaecologist) and Ms Patty Chondros (non-voting
member and statistician for the trial). This committee will
meet three times, with two interim analyses review meet-
ings scheduled to occur when 126 and 252 women have
been recruited. O'Brien and Fleming's procedure and
stopping rules [28] will be employed with the nominal p
value of 0.0005 at the first meeting and 0.014 at the sec-
ond. To allow for the loss of power due to two interim
analyses and the final analysis, the target sample of
women providing outcome data is inflated by a factor of
1.017 from 372 to 380 women. The Data Monitoring
Committee will examine reports of side-effects of the
interventions at each of its meetings.
Outcomes
The primary outcome is symptomatic vulvovaginal candi-
diasis, which is defined as participants' report of symp-
toms (that is answer 'yes' to a question about symptoms
of 'thrush' in survey 2: vaginal itch, irritation with or with-
out a discharge) and swab B culture positive for Candida
species.
Data analysis
Analysis is intention-to-treat with two pre-specified main
comparisons: (i) oral lactobacillus versus placebo and (ii)
vaginal lactobacillus versus placebo, using Stata version 7
[27]. Categorical baseline characteristics will be described
as frequencies and percentages for each factorial group, to
assess whether potential confounders are balanced across
the groups. Differences in baseline characteristics between
women who provided outcome data and those who did
not will be examined using Pearson chi-square statistic for
categorical variables and two-sample t-test for age. The
numbers of PAV cases will be reported as percentages with
95% confidence intervals (CIs). Logistic regression will be
used to examine whether active pessaries or active powder
are effective in preventing PAV. The results of the outcome
will be reported as odds ratios (ORs) with 95% CIs. Treat-
ment interaction between oral and vaginal interventions
will also examined in the logistic model.
Sensitivity analyses will be carried out whereby partici-
pants with incomplete outcome data (no swab B) who
report symptoms of PAV or who provide no outcome data
are treated as non-PAV cases in the first scenario and as
PAV cases in the second scenario. Contacted non-compl-
eters who report no symptoms of PAV will be treated as
non-PAV cases in both scenarios.
Trial organisation
Ethics and ethical issues
The trial has received ethics approval from both the Royal
Australian College of General Practitioners and the Royal
Women's Hospital, Melbourne, Australia.
Women are required to provide written informed consent
(Additional file: appendix 2) prior to entering the trial and
are free to withdraw at any time.
As both interventions being tested in the trial are available
over-the-counter, it is not anticipated that there will be
any major risks to participants. Women may benefit if ran-
domised to an active intervention, but this is not known.
The inconveniences to participants include providing two
vaginal swabs and taking oral and vaginal medications for
ten days. Side-effects of the interventions will be
monitored and reviewed at each of the Data Monitoring
Committee's meetings. Any serious problems will be
reported to both of the ethics committees involved.
Personel
The trial investigators are Dr Marie Pirotta (Department of
General Practice, University of Melbourne), Associate Pro-
fessor Jane Gunn (Department of General Practice, Uni-
versity of Melbourne), Associate Professor Suzanne
Garland (Department of Microbiology & Infectious Dis-
eases, Royal Women's Hospital, Melbourne), Dr SusanBMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/5
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Hurley, Dr Sonia Grover (Senior Obstetrician, Royal
Women's Hospital, Melbourne), Ms Patty Chondros (stat-
istician, Department of General Practice, University of
Melbourne) and Ms Cate Nagle holds the randomisation
schedule. The research assistants are Paula O'Malley, Kitty
Novy and Belinda Clarke.
The reference group comprises Dr Lisa Amir, general prac-
titioner and lactation consultant with a research interest
in candidiasis of the nipple; Dr Trish Boetto, general prac-
titioner and practitioner of Nutritional and Environmen-
tal medicine; Dr Liz Gorczyca, scientist at RMIT with a
research interest in food-based lactobacilli; Ms Gail Rob-
erts, a consumer, who has worked in various health
related areas and been a board member of the Health
Issues Centre and Mrs Keri Jones, Assistant Lecturer,
Department of Pharmaceutics, Victorian College of Phar-
macy, Parkville.
Administration
A database of recruiters is constructed and maintained to
keep track of all the recruiting general practitioners and
pharmacists. A research assistant is responsible for provid-
ing feedback to recruiters after each referral. A successful
referral receives a telephone call and then a postcard
advising the recruiter of the success of the referral. Unsuc-
cessful referrals receive a postcard advising why the refer-
ral failed in order to remind referrers if trial criteria have
not been fulfilled. MP and POM create and mail regular
newsletters to the recruiting network to maintain the net-
work of recruiters' enthusiasm and support for the trial.
When a new participant enters the trial, it is necessary to
ensure all the initial paperwork is complete (consent
form, survey 1, swab A and recruiter survey), arrange for
collection of trial data as soon as possible from the clinic
to ensure there are no problems, and that swab A has
arrived at the laboratory. The survey 1, recruiters survey
and consent form are then checked, coded, entered into
the Access database and filed in a locked filing cabinet.
Participants receive a welcome call within 24 hours if
enrolled by a community-based recruiter.
Trial registration
The importance of trial registration has been emphasized
in the literature as a method to reduce publication bias
[29]. The PAV trial was registered in the UK (registration
number number: ISRCTN24141277).
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